MRK Merck & Co., Inc.
Merck & Co., Inc. (MRK) trend channel, buy level and 3-month target on Trade The Path. Sector: Healthcare. Listed on NYSE. Levels below are fitted to this ticker's own swing highs and lows (Theil–Sen, log-price), then projected 3 months. On this symbol, 5 comparable calls have settled; 20% reached the published sell target. Information only, not financial advice.
Broken out above
Price has closed above the channel. The fitted trend may no longer describe this stock.
Read from the last 9 months of history we hold: rising, drifting +43% a year. Price is above both fitted ceilings, so there is no line overhead to break — and no fitted resistance to price the target against either. What would overturn this: a close below US$116.39 — the floor of the channel being read — after which the trend, not the entry, is what was wrong.
- 9 months read from
- US$116.39 – US$139.14 Rising channel, +43% a year
- Position in that channel
- 125% above the ceiling of it — 0% is the floor, 100% the ceiling
Price history, with the path projected 3 months forward
- Daily close
- Upper trend line (9 months)
- Lower trend line (9 months)
- Dashed after today: projected 3 months
- Our buy
- Our target
Our target
We replayed these rules over this stock's own history and the target was reached on only 1 of 5 calls. Its swings do not respect the channel reliably enough for a published call, and no alerts are sent. The numbers below are still this site's read of the fitted channel.
Buy at or below
US$116.40
level as at 17 Sept 2026
Our target
US$146.81
by 16 Dec 2026
Projected move
26.1%
gross, before costs
Price sits between our buy level and our target.
On this stock's own history these rules produced 5 settled calls, of which 1 reached target (20%), with an average best move of 8.3%. See the full record.
- Upper line touches
- 3
- Lower line touches
- 3
- Fit confidence
- 55%
- Fitted
- 16 Sept 2026
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis
- Employees
- 74,000
- Country
- US
Scorecard
Our own pillar scores, computed from the fundamentals below. They are not Morningstar ratings — that data is licensed and we do not redistribute it.
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$355.49B
- Enterprise value
- —
- Beta
- 0.23
- Avg volume
- 10.17M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 77.58-156.92
- Exchange
- NYSE
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted statistically to past swing highs and lows and projected forward on the assumption the same rhythm continues. It often does not. This is information, not advice.